In order to further improve the detection capabilities of the new coronavirus, the National Medical Insurance Administration provides orderly guidance to reduce the relatively high testing costs, and supports the realization of "all tests should be done and all tests are willing to be done", and we will do a good job in the registration of new coronavirus testing. Notices were issued on online procurement, price management and medical insurance payment. The notice made it clear that the needs for the prevention and control of new coronavirus pneumonia must be comprehensively considered.
Based on factors such as the paying capacity of the local medical insurance fund, nucleic acid and antibody testing projects and related consumables for the new coronavirus will be included in the catalog of provincial medical insurance diagnosis and treatment projects according to procedures, and payment conditions will be determined simultaneously. The notice pointed out that reagent procurement channels should be smoothed. Open online procurement is widely carried out.
Pharmaceutical centralized procurement agencies in various regions should do a good job in linking new coronavirus testing reagents to the Internet, and improve the information sharing and price linkage mechanism between provincial centralized procurement platforms. Public medical institutions should purchase new coronavirus testing reagents from Sunshine, the provincial centralized procurement platform for pharmaceutical consumables in their province.
Extended information:
In terms of improving the price policy for testing items, the notice emphasized that testing items are not “based on disease.” In principle, new nucleic acid and antibody testing price items will be established without distinguishing between pathogens or operating steps; related inspections for Class A infectious diseases or infectious diseases managed according to Class A according to the law, if the risks are difficult and the protection requirements are high, they can be formulated on the basis of prevailing price items Uniform surcharge policy.
Public medical institutions that carry out nucleic acid and antibody testing for the new coronavirus can directly implement existing charging policies and do not need to apply for new price items. If it is really necessary to set up temporary projects to meet the new coronavirus testing charging needs of public medical institutions, localities are encouraged to establish projects in a "separation of technology and consumption" approach.
China Government Website-National Medical Insurance Administration: All localities should include nucleic acid testing items in medical insurance according to procedures